在全球日益关注的食物浪费问题中,抗肥胖药物,特别是胰高血糖素样肽-1激动剂(GLP1A),正被越来越多地用于调节消费者的饮食习惯。由俄亥俄州立大学科研团队撰写并发表在《Nutrients》期刊的文章《Changes in Food Waste among a Sample of U...
and in some ways it was a bit of a surprise. One wouldn’t necessarily think of this as an effective modality. It’s a widely available medication. So I think it’s very exciting that there’s another option.
5 U.S. Food & Drug Administration, “FDA Approves New Medication for Chronic Weight Management,” November 2023 6 PBS, “The many ways new weight loss drugs could transform the economy,” June 2024 7 MarketWatch, “Obesity drugs’ next wave: These companies could snag 20% of GLP-1 market...
这种“瘦身营养素”更安全 今年6月,有“减肥神药”之称的司美格鲁肽(GLP-1)在国内获批,用于体重管理的适应症。 这是很多超重和肥胖症患者的福音,GLP-1的减重机制是控制食欲。但是,随之而来的是它的一系列负面报道,比如会引起男性性功能障碍、胃肠道不适、疲倦无力、皮肤松垮、视网膜病变和急性肾损伤等症状。此...
The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients who are 10 years old and up with Type 2 diabetes. The liraglutide injection, which is currently in shortage and sold under the bran
With all the buzz around GLP-1 medicines’ ability to promote weight loss, it can be easy to think of them as miracle drugs — a one-and-done solution for both weight and diabetes management. But medication is just part of the equation. Exercise, diet and continuous glucose monitoring can...
(以下简称:甘李药业,股票代码:603087.SH)宣布,子公司甘李药业山东有限公司申报的1类创新型治疗用生物制品GZR18片,已收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》(受理号:CXSL2300633、CXSL2300634、CXSL2300635,批准通知书编号:2023LP02424、2023LP02425、2023LP02426),获批适应症为2型糖尿...
Acting as a GLP-1 receptor agonist, it cleverly replicates a hormone that your body already uses to regulate blood sugar, making it an invaluable tool in your weight loss arsenal. Semaglutide is administered by injecting the medication into the fatty area around your love handles, using a short...
5.1 million obtained a GLP-1 medication—dulaglutide, exenatide, liraglutide, semaglutide, or tirzepatide. Many of them—41.2%—initiated the treatment that year. The average annual expenditure on GLP-1 drugs for the adults with type 2 diabetes who used them in 2022 totaled $6684 per p...
礼来公司（Eli Lilly and Co.）是Zepbound和Mounjaro的制造商，该公司周四宣布其针对一种每日一次的GLP-1口服片剂进行的第三阶段临床试验成功。这种口服片剂是用于糖尿病和减肥的畅销药物的一种形式。对于药物orforglipron的试验，其疗效和安全性在2型糖尿病患者中与安慰剂进行了比较。试验发现，在40周后，不同剂量...